Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trials
- DOI
- 10.1016/j.esmoop.2026.106091
- Published
- 2026-03
- Container
- ESMO Open
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.esmoop.2026.106091,
title = {Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trials},
author = {K. Jhaveri and F.C. Bidard and K. Kalinsky and P. Neven and H.S. Rugo and S.M. Tolaney and L.M. Litchfield and C.C. von Laue and S. Traore and F. Sapunar and Y. Li and J. O’Shaughnessy},
year = {2026},
journal = {ESMO Open},
doi = {10.1016/j.esmoop.2026.106091},
url = {https://doi.org/10.1016/j.esmoop.2026.106091}
}RIS
TY - JOUR TI - Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trials AU - K. Jhaveri AU - F.C. Bidard AU - K. Kalinsky AU - P. Neven AU - H.S. Rugo AU - S.M. Tolaney AU - L.M. Litchfield AU - C.C. von Laue AU - S. Traore AU - F. Sapunar AU - Y. Li AU - J. O’Shaughnessy PY - 2026 JO - ESMO Open DO - 10.1016/j.esmoop.2026.106091 UR - https://doi.org/10.1016/j.esmoop.2026.106091 ER -
APA
Jhaveri, K., Bidard, F., Kalinsky, K., Neven, P., Rugo, H., Tolaney, S., Litchfield, L., Laue, C. V., Traore, S., Sapunar, F., Li, Y., & O’Shaughnessy, J. (2026). Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trials. ESMO Open. https://doi.org/10.1016/j.esmoop.2026.106091
Source records
- crossref · retrieved 2026-09-27T13:10:18.455Z